CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Rocket Pharmaceuticals Closes $180 Million Sale of Pediatric Priority Review Voucher

Positive
AI Analysis

Summary

Rocket Pharmaceuticals closed the sale of a pediatric priority review voucher for $180 million, a regulatory asset that can be used to expedite FDA review of a new drug application.

Importance:6/10
Sentiment:
0.70
pediatricpriority review voucherasset salefinancing
Related Companies

Read the original article

Published by yahoo_finance on June 12, 2026 11:49 AM

Read Original